Astrazeneca (AZN) Non-cash Items (2009 - 2026)

Astrazeneca's Non-cash Items history runs 18 years deep, the most recent figure standing at $4.3 billion for Q1 2026.

• In Q1 2026, Non-cash Items fell 3.82% year-over-year to $4.3 billion; the TTM figure through Mar 2026 stood at $4.3 billion (down 3.82% YoY), while the FY2025 annual figure was $18.7 billion, up 17.66% from the prior year.
• Non-cash Items was $4.3 billion for Q1 2026 at Astrazeneca, down from $18.7 billion in the prior quarter.
• In the past five years, Non-cash Items ranged from a high of $18.7 billion in Q4 2025 to a low of $3.3 billion in Q1 2024.
• Historically, Non-cash Items has averaged $8.5 billion across 5 years, with a median of $6.4 billion in 2023.
• The sharpest annual moves came in 2022 and 2024: Non-cash Items surged 88.53% in 2022, then fell 9.9% in 2024.
• A 5-year view of Non-cash Items shows it stood at $5.9 billion in 2022, then rose by 8.91% to $6.4 billion in 2023, then jumped by 149.01% to $15.9 billion in 2024, then rose by 17.66% to $18.7 billion in 2025, then plunged by 76.91% to $4.3 billion in 2026.
• The last three Non-cash Items figures came in at $4.3 billion (Q1 2026), $18.7 billion (Q4 2025), and $15.5 billion (Q3 2025), per Business Quant data.